426 related articles for article (PubMed ID: 23147664)
21. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
23. Systemic therapy of hepatocellular carcinoma: current and promising.
Kalyan A; Nimeiri H; Kulik L
Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
[TBL] [Abstract][Full Text] [Related]
24. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
Kudo M; Lencioni R; Marrero JA; Venook AP; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Ye SL
Liver Int; 2016 Aug; 36(8):1196-205. PubMed ID: 26901163
[TBL] [Abstract][Full Text] [Related]
25. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.
Qi X; Zhao Y; Li H; Guo X; Han G
Oncotarget; 2016 Jun; 7(23):34703-51. PubMed ID: 27167195
[TBL] [Abstract][Full Text] [Related]
26. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
27. Liver tumors and loco-regional therapy.
Vogel W
Wien Med Wochenschr; 2013 Mar; 163(5-6):107-8. PubMed ID: 23456251
[No Abstract] [Full Text] [Related]
28. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma.
Daoudaki M; Fouzas I
Wien Med Wochenschr; 2014 Nov; 164(21-22):450-5. PubMed ID: 25182146
[TBL] [Abstract][Full Text] [Related]
30. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Lorenzin D; Pravisani R; Leo CA; Bugiantella W; Soardo G; Carnelutti A; Umberto B; Risaliti A
Cancer Biother Radiopharm; 2016 Mar; 31(2):65-9. PubMed ID: 26986817
[TBL] [Abstract][Full Text] [Related]
31. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
Takano M; Kokudo T; Miyazaki Y; Kageyama Y; Takahashi A; Amikura K; Sakamoto H
World J Gastroenterol; 2016 Nov; 22(42):9445-9450. PubMed ID: 27895433
[TBL] [Abstract][Full Text] [Related]
32. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
33. Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Huang YH; Chen W; Li JP; Chen B; Yang JY
Chin Med J (Engl); 2013 Jan; 126(2):385-6. PubMed ID: 23324295
[No Abstract] [Full Text] [Related]
34. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
Schwarz RE; Abou-Alfa GK; Geschwind JF; Krishnan S; Salem R; Venook AP; ; ;
HPB (Oxford); 2010 Jun; 12(5):313-20. PubMed ID: 20590905
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma: clinical frontiers and perspectives.
Bruix J; Gores GJ; Mazzaferro V
Gut; 2014 May; 63(5):844-55. PubMed ID: 24531850
[TBL] [Abstract][Full Text] [Related]
36. Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil.
Almeida-Carvalho SR; Gomes-Ferraz ML; Loureiro-Matos CA; Benedito-Silva AT; Carvalho-Filho RJ; Renato-Perez R; Miziara-Gonzalez A; Salzedas-Netto AA; Szejnfeld D; D'Ippolito G; Pereira-Lanzoni V; Souza-Silva I
Ann Hepatol; 2017; 16(2):255-262. PubMed ID: 28233747
[TBL] [Abstract][Full Text] [Related]
37. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
[TBL] [Abstract][Full Text] [Related]
38. Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma.
Yoon HI; Seong J
Oncology; 2014; 87 Suppl 1():90-8. PubMed ID: 25427739
[TBL] [Abstract][Full Text] [Related]
39. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Ohki T; Kondo M; Karasawa Y; Kawamura S; Maeshima S; Kojima K; Seki M; Toda N; Shioda Y; Tagawa K
Adv Ther; 2017 May; 34(5):1097-1108. PubMed ID: 28389996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
